Inhibikase Therapeutics, Inc. (IKT)
$1.76-4.86%Close
SELLCRISIS · day 15
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $232M
- Beta
- 0.90
- P/E (TTM)
- -3.70
- Short % float
- 12.03%
- Days to cover
- 27.0
- SI change
- +4.9%
- 1W
- -11.11%
- 1M
- -26.36%
- vs SPY 1W
- -10.97%
- vs SPY 1M
- -28.87%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 4
- VALUE
- 5
- GROWTH
- 39
- GARP
- 0
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-25.7%
REV YoY-
ROE-42.8%
EPS YoY-
ROA-37.1%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-3.70
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B2.00
P/FCF-
EV/EBITDA-3.23
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E-
ALTMAN Z-
CURR RATIO15.82
ND/EBITDA-
BETA0.90
Company news
FAQ
- What is LOPJLB’s current signal on IKT?
- LOPJLB’s latest quantitative signal on Inhibikase Therapeutics, Inc. (IKT) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is IKT in?
- Inhibikase Therapeutics, Inc. (IKT) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Inhibikase Therapeutics, Inc. (IKT) do?
- Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of i…